<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520998</url>
  </required_header>
  <id_info>
    <org_study_id>ALK6019-201</org_study_id>
    <nct_id>NCT03520998</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkahest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkahest, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, tolerability, and feasibility of GRF6019, a
      plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild
      to moderate Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, dose-comparison concurrent control study to assess the
      safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered by
      intravenous (IV) infusion to subjects with mild to moderate Alzheimer's disease.

      Subjects will be randomized 1:1 to a low dose or a high dose of active treatment in a
      double-blind manner. All subjects will receive one infusion per day at the randomized dose
      for 5 consecutive days during Week 1 and, again, during Week 13 (for a total of 10 doses per
      subject). All IV infusions will take place at an inpatient research unit while the follow-up
      visits after each treatment period will be on an outpatient basis. Subjects will participate
      for a total of 6 months in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in scores on the MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in scores on the 11-item ADASCog/11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Grooved Pegboard Test</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in scores on the Grooved Pegboard Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Category Fluency Test (CFT)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in scores on the CFT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in the CDR-SOB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in the ADCS-ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCSCGIC)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes on the ADCSCGIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Neuropsychiatric Inventory Questionnaire (NPI-Q)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change on the NPI-Q</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Savonix Neurocognitive Assessments and Digit Span</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change on the Savonix Neurocognitive Assessments and Digit Span</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild to Moderate Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>GRF6019 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRF6019 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRF6019</intervention_name>
    <description>GRF6019 for IV infusion</description>
    <arm_group_label>GRF6019 Low Dose</arm_group_label>
    <arm_group_label>GRF6019 High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable AD based upon the National Institute on Aging-Alzheimer's
             Association (NIA-AA) Criteria

          -  MMSE Score 12-24 inclusive

          -  Modified Hachinski Ischemia Scale (MHIS) score of â‰¤ 4

          -  Provided a signed and dated informed consent form (either the subject and/or subject's
             legal representative as well as the trial partner)

        Exclusion Criteria:

          -  Evidence of clinically relevant neurological disorder(s) other than probable AD

          -  History of blood coagulation disorders or hypercoagulability; any concurrent use of an
             anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa
             inhibitors). Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable.

          -  Initiation or change in the dosage of cholinesterase inhibitors (AChEI), memantine,
             Axona, vitamin E supplementation or selegiline within 3 months prior to screening.

          -  Heart disease (or history thereof), as evidenced by myocardial infarction, unstable,
             new onset or severe angina, or congestive heart failure (New York Association Class
             II, III or IV) in the 6 months prior to dosing; uncontrolled high blood pressure
             (systolic blood pressure of 160 mmHg or higher and/or diastolic blood

          -  Prior hypersensitivity reaction to any human blood product or intravenous infusion;
             any known clinically significant drug allergy.

          -  Treatment with any human blood product, including transfusions and intravenous
             immunoglobulin, during the 6 months prior to screening.

          -  History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency; stroke,
             anaphylaxis, or thromboembolic complications of intravenous immunoglobulins.

          -  Hemoglobin &lt;10 g/dL in women; and &lt;11 g/dL in men.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkahest Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Alkahest, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alkahest Medical Monitor</last_name>
    <phone>650-801-0474</phone>
    <email>trials@alkahest.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Synergy East</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Synergy East</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CNS Network</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pacific Research Network</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD Clinical</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Princeton Medical Institute</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Serenity Inpatient</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serenity Inpatient</last_name>
      <email>trials@alkahest.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

